CD8A and neoplasm: The ONCOS-210 and ONCOS-212 treatment groups expressed significantly higher percentages of granzyme B+ CD8+ T cells in the TILs of their respective day 28 A2058 tumors than vehicle control (Figure 7), indicating that immune mechanisms involving activated CD8+ T cells contributed to the reduction in tumor volumes.